Interferon activation in primary Sjögren’s syndrome: recent insights and future perspective as novel treatment target

References

• Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11:1–16.
   Web of Science ®Google Scholar
• Fox RI, Howell FV, Bone RC, et al. Primary sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum. 1984;14:77–105.
   PubMed Web of Science ®Google Scholar
• Asmussen K, Andersen V, Bendixen G, et al. A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996;239:475–482.
   PubMed Web of Science ®Google Scholar
• Virus interference. I.. The interferon. Proc Royal Soc London Ser B Biol Sci. 1957;147:258–267.
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8–32.
   PubMed Web of Science ®Google Scholar
• Eloranta M-L, Alm GV, Rönnblom L. Disease mechanisms in rheumatology—tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases. Arthritis Rheum. 2013;65:853–863.
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–189.
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Gallagher G, Baurin VV, et al. IFN-[lambda]s mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R, Nat Immunol. 2003;4:63–68.
   PubMed Web of Science ®Google Scholar
• Oishi A, Miyamoto K, Kashii S, et al. Abducens palsy and Sjögren’s syndrome induced by pegylated interferon therapy. Br J Ophthalmol. 2007;91:843–844.
   PubMed Web of Science ®Google Scholar
• Ojha JBI, Islam N, Cohen DM, et al. Xerostomia and lichenoid reaction in a hepatitis C patient treated with interferon-alpha: a case report. Quintessence Int. 2008;39:343–348.
   PubMed Web of Science ®Google Scholar
• Deshmukh Umesh S, Nandula Seshagiri R, Thimmalapura PR, et al. Activation of innate immune responses through Toll‐like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med. 2009;38:42–47.
   PubMed Web of Science ®Google Scholar
• Nandula SR, Dey P, Corbin Kathryn L, et al. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. J Oral Pathol Med. 2013;42:66–72.
   PubMed Web of Science ®Google Scholar
• Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjögren’s syndrome: A putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008;38:2024–2033.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci U S A. 2006;103:2770–2775.
   PubMed Web of Science ®Google Scholar
• Hjelmervik TOR, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren’s syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52:1534–1544.
   PubMed Web of Science ®Google Scholar
• Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjogren’s syndrome. Genes Immun. 2009;10:285–296.
   PubMed Web of Science ®Google Scholar
• Imgenberg-Kreuz J, Sandling JK, Almlöf JC, et al. Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren’s syndrome reveals regulatory effects at interferon-induced genes. Ann Rheum Dis. 2016;75:2029–2036.
   PubMed Web of Science ®Google Scholar
• Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72:728–735.
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci. 2012;109:17609–17614.
   PubMed Web of Science ®Google Scholar
• Hall JC, Baer AN, Shah AA, et al. Molecular subsetting of interferon pathways in Sjögren’s syndrome. Arthritis Rheumatol. 2015;67:2437–2446.
   PubMed Web of Science ®Google Scholar
• Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis rheumatol (Hoboken, N J). 2014;66:1583–1595.
   PubMed Web of Science ®Google Scholar
• Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Rheumatology. 2018;57:921–930.
   PubMed Web of Science ®Google Scholar
• Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J Autoimmun. 2015;63:47–58.
   PubMed Web of Science ®Google Scholar
• El-Sherbiny YM, Psarras A, Yusof MYM, et al. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018;8:5793.
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018. doi: 10.1136/annrheumdis-2018-213386
   PubMedGoogle Scholar
• Apostolou E, Kapsogeorgou EK, Konsta OD, et al. Expression of type III interferons (IFNλs) and their receptor in Sjögren’s syndrome. Clin Exp Immunol. 2016;186:304–312.
   PubMed Web of Science ®Google Scholar
• Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary Sjögren’s syndrome: A possible etiopathogenic mechanism. Arthritis Rheum. 2005;52:1185–1195.
   PubMed Web of Science ®Google Scholar
• Maria NI, Steenwijk EC, Ijpma AS, et al. Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2016;76:721–730.
   PubMed Web of Science ®Google Scholar
• Lövgren T, Eloranta M-L, Kastner B, et al. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen– and Sjögren’s syndrome autoantigen–associated RNA. Arthritis Rheum. 2006;54:1917–1927.
   PubMed Web of Science ®Google Scholar
• Båve U, Alm GV, Rönnblom L. The Combination of Apoptotic U937 Cells and Lupus IgG Is a Potent IFN-α Inducer. J Immunol. 2000;165:3519–3526.
   PubMed Web of Science ®Google Scholar
• Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005;115:407–417.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Sagalovskiy I, Guo Q, et al. Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease. Arthritis Rheumatol. 2016;68:2686–2696.
   PubMed Web of Science ®Google Scholar
• Ainola M, Porola P, Takakubo Y, et al. Activation of plasmacytoid dendritic cells by apoptotic particles – mechanism for the loss of immunological tolerance in Sjögren’s syndrome. Clin Exp Immunol. 2018;191:301–310.
   PubMed Web of Science ®Google Scholar
• Zhao K, Du J, Peng Y, et al. LINE1 contributes to autoimmunity through both RIG-I- and MDA5-mediated RNA sensing pathways. J Autoimmun. 2018;90:105–115.
   PubMed Web of Science ®Google Scholar
• Lee KH, Kronbichler A, Park DD-Y, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review. Autoimmun Rev. 2017;16:1160–1173.
   PubMed Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-dna–peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra19–73ra19.
   PubMed Web of Science ®Google Scholar
• Meng H, Yalavarthi S, Kanthi Y, et al. In vivo role of neutrophil extracellular traps in antiphospholipid antibody–mediated venous thrombosis. Arthritis Rheumatol. 2017;69:655–667.
   PubMed Web of Science ®Google Scholar
• Sur Chowdhury C, Giaglis S, Walker UA, et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014;16:R122.
   PubMed Web of Science ®Google Scholar
• Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra20–73ra20.
   PubMed Web of Science ®Google Scholar
• Tan L, Wu H, Liu Y, et al. Recent advances of exosomes in immune modulation and autoimmune diseases. Autoimmunity. 2016;49:357–365.
   PubMed Web of Science ®Google Scholar
• Lee JY, Park JK, Lee EY, et al. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther. 2016;18:264.
   PubMed Web of Science ®Google Scholar
• Salvi V, Gianello V, Busatto S, et al. Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7. JCI Insight. 2018;3:e98204.
   Web of Science ®Google Scholar
• Paludan SR, Bowie AG. Immune sensing of DNA. Immunity. 2013;38:870–880.
   PubMed Web of Science ®Google Scholar
• Papinska J, Bagavant H, Gmyrek GB, et al. Activation of Stimulator of Interferon Genes (STING) and Sjögren Syndrome. J Dent Res. 2018;97:893–900.
   PubMed Web of Science ®Google Scholar
• Alunno A, Caneparo V, Carubbi F, et al. Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary Sjögren’s syndrome: findings in serum and minor salivary glands. Reumatismo. 2016 ;67:6.
   Web of Science ®Google Scholar
• Baer Alan N, Petri M, Sohn J, et al. Association of antibodies to interferon-inducible protein-16 with markers of more severe disease in primary Sjögren’s syndrome. Arthritis Care Res. 2016;68:254–260.
   Web of Science ®Google Scholar
• Wahadat MJ, Bodewes ILA, Maria NI, et al. Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? Arthritis Res Ther. 2018;20:4.
   PubMed Web of Science ®Google Scholar
• Argyrios NT, Roberto B, Bruce B, et al. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307–335.
   PubMed Web of Science ®Google Scholar
• Kirou KA, Mavragani CP, Crow MK. Activation of type I interferon in systemic lupus erythematosus. Expert Rev Clin Immunol. 2007;3:579–588.
   PubMedGoogle Scholar
• Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren’s syndrome. Arthritis Res Ther. 2006;8:R51.
   PubMed Web of Science ®Google Scholar
• Kiefer K, Oropallo Michael A, Cancro Michael P, et al. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol. 2012;90:498–504.
   PubMed Web of Science ®Google Scholar
• Manoussakis MN, Kapsogeorgou EK. The role of intrinsic epithelial activation in the pathogenesis of Sjögren’s syndrome. J Autoimmun. 2010;35:219–224.
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for baff develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697–1710.
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest. 2002;109:59–68.
   PubMed Web of Science ®Google Scholar
• Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren’s syndrome. Arthritis Rheum. 2007;56:1134–1144.
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli‐Richard C, Ittah M, et al. B‐cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren’s syndrome. Scand J Immunol. 2008;67:185–192.
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis. 2003;62:168–171.
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli‐Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren’s syndrome. J Pathol. 2004;202:496–502.
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck J-P, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19:225–234.
   PubMed Web of Science ®Google Scholar
• Jonsson R, Theander E, Sjöström B, et al. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA. 2013;310:1854–1855.
   PubMed Web of Science ®Google Scholar
• Theander E, Jonsson R, Sjöström B, et al. Prediction of Sjögren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol. 2015;67:2427–2436.
   PubMed Web of Science ®Google Scholar
• Risselada AP, Looije MF, Kruize AA, et al. The role of ectopic germinal centers in the immunopathology of primary Sjögren’s syndrome: a systematic review. Semin Arthritis Rheum. 2013;42:368–376.
   PubMed Web of Science ®Google Scholar
• Skopouli FN, Dafni U, Ioannidis JPA, et al. Clinical evolution, and morbidity and mortalityof primary Sjögren’s syndrome. Semin Arthritis Rheum. 2000;29:296–304.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46:741–747.
   PubMed Web of Science ®Google Scholar
• Theander E, Manthorpe R, Jacobsson LTH. Mortality and causes of death in primary Sjögren’s syndrome: A prospective cohort study. Arthritis Rheum. 2004;50:1262–1269.
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Ramos-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology. 2007;46:1359–1362.
   PubMed Web of Science ®Google Scholar
• Sène D, Ismael S, Forien M, et al. Ectopic germinal centre‐like structures in minor salivary gland biopsy predict lymphoma occurrence in patients with primary Sjögren syndrome. Arthritis Rheumatol. 2018;70:1481–1488.
   Google Scholar
• Manoussakis Menelaos N, Dimitriou Ioannis D, Kapsogeorgou Efstathia K, et al. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren’s syndrome. Arthritis Rheum. 1999;42:229–239.
   PubMedGoogle Scholar
• Ogawa N, Ping L, Zhenjun L, et al. Involvement of the interferon‐γ–induced T cell–attracting chemokines, interferon‐γ–inducible 10‐kd protein (CXCL10) and monokine induced by interferon‐γ (CXCL9), in the salivary gland lesions of patients with Sjögren’s syndrome. Arthritis Rheum. 2002;46:2730–2741.
   PubMed Web of Science ®Google Scholar
• Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, et al. Induction of salivary gland epithelial cell injury in sjogren’s syndrome: in vitro assessment of t cell-derived cytokines and fas protein expression. J Autoimmun. 2001;17:141–153.
   PubMed Web of Science ®Google Scholar
• Kulkarni K, Selesniemi K, Brown TL. Interferon-gamma sensitizes the human salivary gland cell line, HSG, to tumor necrosis factor-alpha induced activation of dual apoptotic pathways. Apoptosis. 2006;11:2205.
   PubMed Web of Science ®Google Scholar
• Nguyen Cuong Q, Hu Min H, Li Y, et al. Salivary gland tissue expression of interleukin‐23 and interleukin‐17 in Sjögren’s syndrome: findings in humans and mice. Arthritis Rheum. 2008;58:734–743.
   PubMedGoogle Scholar
• Sakai A, Sugawara Y, Kuroishi T, et al. Identification of IL-18 and th17 cells in salivary glands of patients with Sjögren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol. 2008;181:2898–2906.
   PubMed Web of Science ®Google Scholar
• Nguyen CQ, Yin H, Lee BH, et al. Pathogenic effect of interleukin-17A in induction of Sjögren’s syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther. 2010;12:R220–R.
   PubMed Web of Science ®Google Scholar
• Verstappen GM, Corneth OBJ, Bootsma H, et al. Th17 cells in primary Sjögren’s syndrome: pathogenicity and plasticity. J Autoimmun. 2018;87:16–25.
   PubMed Web of Science ®Google Scholar
• Szabo K, Papp G, Barath S, et al. Follicular helper T cells may play an important role in the severity of primary Sjögren’s syndrome. Clin Immunol. 2013;147:95–104.
   PubMed Web of Science ®Google Scholar
• Gong Y-Z, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome. J Autoimmun. 2014;51:57–66.
   PubMed Web of Science ®Google Scholar
• Izumi Y, Ida H, Huang M, et al. Characterization of peripheral natural killer cells in primary Sjögren’s syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med. 2006;147:242–249.
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Nocturne G, Lazure T, et al. NCR3/NKp30 contributes to pathogenesis in primary Sjögren’s syndrome. Sci Transl Med. 2013;5:195ra96–ra96.
   PubMed Web of Science ®Google Scholar
• Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34:400–407.
   PubMed Web of Science ®Google Scholar
• van der Vliet HJJ, von Blomberg BME, Nishi N, et al. Circulating Vα24+ Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001;100:144–148.
   PubMed Web of Science ®Google Scholar
• Chen J, Wu M, Wang J, et al. Immunoregulation of NKT cells in systemic lupus erythematosus. J Immunol Res. 2015;2015:8.
   Google Scholar
• Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, et al. Foxp3+ T-regulatory cells in Sjögren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol. 2008;173:1389–1396.
   PubMed Web of Science ®Google Scholar
• Li X, Li X, Qian L, et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren’s syndrome. J Rheumatol. 2007;34:2438–2445.
   PubMed Web of Science ®Google Scholar
• Alunno A, Petrillo MG, Nocentini G, et al. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren’s syndrome. Rheumatology. 2013;52:1387–1396.
   PubMed Web of Science ®Google Scholar
• Sarigul M, Yazisiz V, Başsorgun CI, et al. The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren’s syndrome. Lupus. 2009;19:138–145.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Lavie F, Abbed K, et al. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren’s syndrome. J Autoimmun. 2005;24:235–242.
   PubMed Web of Science ®Google Scholar
• Legány N, Berta L, Kovács L, et al. The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren’s syndrome and systemic sclerosis. Immunol Res. 2017;65:622–629.
   PubMed Web of Science ®Google Scholar
• Furuzawa-Carballeda J, Hernández-Molina G, Lima G, et al. Peripheral regulatory cells immunophenotyping in primary Sjögren’s syndrome: a cross-sectional study. Arthritis Res Ther. 2013;15:R68.
   PubMed Web of Science ®Google Scholar
• Maria NI, van Helden-Meeuwsen CG, Brkic Z, et al. Increased tregs associated with elevated indoleamine-2,3-dioxygenase activity and an imbalanced kynurenine pathway in IFNpositive primary Sjögren’s syndrome. Arthritis Rheumatol. 2016;68:1688–1699.
   PubMed Web of Science ®Google Scholar
• Mellor AL, Lemos H, Huang L. Indoleamine 2,3-dioxygenase and tolerance: where are we now?. Front Immunol. 2017;8:1360.
   Web of Science ®Google Scholar
• Maria NI, van Helden-Meeuwsen CG, Brkic Z, et al. Association of increased treg cell levels with elevated indoleamine 2,3-dioxygenase activity and an imbalanced kynurenine pathway in interferon-positive primary Sjögren’s syndrome. Arthritis Rheumatol. 2016;68:1688–1699.
   PubMed Web of Science ®Google Scholar
• Pertovaara M, Raitala A, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren’s syndrome. Clin Exp Immunol. 2005;142:155–161.
   PubMed Web of Science ®Google Scholar
• Grohmann U, Orabona C, Fallarino F, et al. CTLA-4–ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3:1097.
   PubMed Web of Science ®Google Scholar
• Downie‐Doyle S, Bayat N, Rischmueller M, et al. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjögren’s syndrome. Arthritis Rheum. 2006;54:2434–2440.
   PubMed Web of Science ®Google Scholar
• Zhu J-M, Li B-K, Chen G-M, et al. CTLA-4-1722T/C polymorphism and systemic lupus erythematosus susceptibility: a meta-analysis involving ten separate studies. Immunol Invest. 2013;42:91–105.
   PubMed Web of Science ®Google Scholar
• Romo-Tena J, Gómez-Martín D, Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev. 2013;12:1171–1176.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Loiseau P, Azarian M, et al. CTLA-4+49A/G and CT60 gene polymorphisms in primary Sjögren syndrome. Arthritis Res Ther. 2007;9:R24.
   PubMed Web of Science ®Google Scholar
• Terawaki S, Chikuma S, Shibayama S, et al. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. 2011;186:2772–2779.
   PubMed Web of Science ®Google Scholar
• Green DS, Young HA, Valencia JC. Current prospects of type II interferon γ signaling and autoimmunity. J Biol Chem. 2017;292:13925–13933.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jin J-O, Du J, et al. Blockade of PD-L1 accelerates the development of Sjögren’s syndrome in non-obese diabetic mice (HUM3P.256). J Immunol. 2015;194(121):16.
   Google Scholar
• Zhou J, Jin J-O, Kawai T, et al. Endogenous programmed death ligand-1 restrains the development and onset of Sjӧgren’s syndrome in non-obese diabetic mice. Sci Rep. 2016;6:39105.
   PubMed Web of Science ®Google Scholar
• Shi H, Ye J, Teng J, et al. Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients. Arthritis Res Ther. 2017;19:52.
   PubMed Web of Science ®Google Scholar
• Danlos F-X, Voisin A-L, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21–29.
   PubMed Web of Science ®Google Scholar
• Calabrese C, Kirchner E, Kontzias A, et al. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3:e000412.
   Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196–202.
   PubMed Web of Science ®Google Scholar
• McBride Jacqueline M, Jiang J, Abbas Alexander R, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64:3666–3676.
   PubMedGoogle Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti–interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011–1021.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1906–1916.
   Web of Science ®Google Scholar
• Ducreux J, Houssiau FA, Vandepapelière P, et al. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study. Rheumatology. 2016;55:1901–1905.
   PubMedGoogle Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, N j). 2017;69:376–386.
   PubMed Web of Science ®Google Scholar
• Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000261.
   PubMed Web of Science ®Google Scholar
• Boedigheimer MJ, Martin DA, Amoura Z, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4:e000226.
   Google Scholar
• Simon S, Galina L, Yakov S, et al. Comparative Clinical Trial of Antibodies to Interferon-Gamma (IFN-¦Ã) and Tumor Necrosis Factor-Alpha (TNF-¦Á) in the treatment of rheumatoid arthritis. J Immune Therapies Vaccines Antimicrob. 2015;4:8.
   Google Scholar
• Valérie DP, Yvon P, Johanne M, et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti‐CD20). Arthritis Care Res. 2007;57:310–317.
   Web of Science ®Google Scholar
• Pijpe J, Imhoff G, Spijkervet FKL, et al. Rituximab treatment in patients with primary Sjögren’s syndrome: an open‐label phase II study. Arthritis Rheum. 2005;52:2740–2750.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71:84–87.
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541–1544.
   Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–968.
   Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary sjögren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014;160:233–242.
   PubMed Web of Science ®Google Scholar
• Simon JB, Colin CE, John LOD, et al. Randomized controlled trial of rituximab and cost‐effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017;69:1440–1450.
   PubMedGoogle Scholar
• Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14:R95–R.
   PubMed Web of Science ®Google Scholar
• Thurlings Rogier M, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62:3607–3614.
   PubMedGoogle Scholar
• Vosslamber S, Raterman HG, van der Pouw Kraan TCTM, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1153–1159.
   PubMed Web of Science ®Google Scholar
• Giltiay NV, Shu GL, Shock A, et al. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling. Arthritis Res Ther. 2017;19:91.
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8:R129.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Dörner T, Bootsma H, et al. Efficacy of epratuzumab, an anti‐CD22 monoclonal igg antibody, in systemic lupus erythematosus patients with associated sjögren’s syndrome: post hoc analyses from the EMBODY trials. Arthritis Rheumatol (Hoboken, N j). 2018;70:763–773.
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526–531.
   Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology. 2015;54:2249–2256.
   PubMed Web of Science ®Google Scholar
• Seror R, Nocturne G, Lazure T, et al. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study. Arthritis Res Ther. 2015;17:241.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Mavragani CP, Nezos A, et al. THU0298 type I interferon predicts biological effect of belimumab on rheumatoid factor positive B-cells in Sjögren’s syndrome: results from the beliss trial. Ann Rheum Dis. 2016;75:294–295.
   Google Scholar
• Lai Kwan Lam Q, King Hung Ko O, Zheng B-J, et al. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci. 2008;105:14993–14998.
   PubMed Web of Science ®Google Scholar
• Dörner T, Posch M, Wagner F, et al. THU0313 double-blind, randomized study of VAY736 single dose treatment in patients with Primary Sjögren’s Syndrome (PSS). Ann Rheum Dis. 2016;75:300–301.
   Google Scholar
• Verstappen Gwenny M, Meiners Petra M, Corneth Odilia BJ, et al. Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017;69:1850–1861.
   PubMed Web of Science ®Google Scholar
• Adler S, Körner M, Förger F, et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary SJögren’s syndrome: a pilot study. Arthritis Care Res. 2013;65:1862–1868.
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese FGM, et al. Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73:1393–1396.
   PubMed Web of Science ®Google Scholar
• van der Heijden EHM, Kruize AA, Radstake TRDJ, et al. Optimizing conventional DMARD therapy for Sjögren’s syndrome. Autoimmun Rev. 2018;17:480–492.
   PubMed Web of Science ®Google Scholar
• Kužnik A, Benčina M, Švajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–4804.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Gudsoorkar VS, Weisman MH, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–28.
   PubMed Web of Science ®Google Scholar
• Suarez-Almazor ME, Belseck E, Shea B, et al. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;4:CD000959.
   Google Scholar
• I Fox R, Dixon R, Guarrasi V, et al. Treatment of primary Sjogren’s syndrome with hydroxychloroqnine: A retrospective, open-label study Lupus. 1996;5:S31–36.
   Web of Science ®Google Scholar
• Tishler M, Yaron I, Shirazi I, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58:253–256.
   PubMed Web of Science ®Google Scholar
• Mumcu G, Biçakçigil M, Yilmaz N, et al. Salivary and Serum B-cell Activating Factor (BAFF) levels after hydroxychloroquine treatment in primary Sjogren’s syndrome. Oral Health Prev Dent. 2013;11:229–234.
   PubMed Web of Science ®Google Scholar
• Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360–364.
   PubMed Web of Science ®Google Scholar
• Çankaya H, Alpöz E, Karabulut G, et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. Oral Surg Oral Medi Oral Pathol Oral Radiol Endodontol. 2010;110:62–67.
   PubMed Web of Science ®Google Scholar
• Gottenberg J, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary sjögren syndrome: the joquer randomized clinical trial. JAMA. 2014;312:249–258.
   PubMed Web of Science ®Google Scholar
• Yoon CH, Lee HJ, Lee EY, et al. Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren’s syndrome: a double-blind randomized control study. J Korean Med Sci. 2016;31:1127–1135.
   PubMed Web of Science ®Google Scholar
• Demarchi J, Papasidero S, Medina MA, et al. Primary Sjögren’s syndrome: extraglandular manifestations and hydroxychloroquine therapy. Clin Rheumatol. 2017;36:2455–2460.
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Baldini C, Alevizos I, et al. Highlights of the 14th International Symposium in Sjögren's Syndrome. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):3–13.
   Google Scholar
• Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14:214.
   PubMed Web of Science ®Google Scholar
• Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a janus kinase inhibitor for dry eye disease: results from a phase 1/2 Trial. Ophthalmology. 2012;119:1328–1335.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee J, Kwok S-K, et al. Janus kinase 1 inhibition suppresses interferon-induced B cell activating factor production in human salivary gland: potential therapeutic strategy for primary Sjögren’s syndrome. Arthritis Rheumatol.
   Google Scholar
• Hasan M, Dobbs N, Khan S, et al. Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice. J Immunol. 2015;195:4573–4577.
   PubMed Web of Science ®Google Scholar
• Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, et al. TBK1: A key regulator and potential treatment target for interferon positive Sjögren’s syndrome, systemic lupus erythematosus and systemic sclerosis. J Autoimmun. 2018;91:97–102.
   PubMed Web of Science ®Google Scholar
• Hasan M, Yan N. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res. 2016;111:336–342.
   PubMed Web of Science ®Google Scholar
• Reilly SM, Chiang S-H, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19:313.
   PubMed Web of Science ®Google Scholar
• Yu T, Yang Y, Yin DQ, et al. TBK1 inhibitors: a review of patent literature (2011 – 2014). Expert Opin Ther Pat. 2015;25:1385–1396.
   PubMed Web of Science ®Google Scholar
• Frémond M-L, Uggenti C, Van Eyck L, et al. Brief Report: blockade of TANK-Binding Kinase 1/IKKɛ Inhibits Mutant Stimulator of Interferon Genes (STING)–mediated inflammatory responses in human peripheral blood mononuclear cells. Arthritis Rheumatol. 2017;69:1495–1501.
   PubMed Web of Science ®Google Scholar
• Sharma S, Campbell AM, Chan J, et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. Proc Natl Acad Sci. 2015;112:E710–E7.
   PubMed Web of Science ®Google Scholar
• Sharma S, Campbell AM, Chan J, et al. II-13 Suppression of systemic autoimmunity by the innate immune adaptor sting. Lupus Sci Med. 2016;3:A21–A2.
   Google Scholar
• Wu Y-W, Tang W, Zuo JP. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015;36:1395–1407.
   PubMed Web of Science ®Google Scholar
• Guiducci C, Ghirelli C, Marloie-Provost M-A, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med. 2008;205:315–322.
   PubMed Web of Science ®Google Scholar
• Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Rheumatology. 2018;91:97–102.
   Google Scholar
• Fisher BA, Jonsson R, Daniels T, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome. Ann Rheum Dis. 2017;76:1161–1168.
   PubMed Web of Science ®Google Scholar
• De Vita LQ S, Salvin S, Picco L, et al. Sequential therapy with belimumab followed by rituximab in Sjögren’s syndrome associated with B-cell lymphoproliferation and overexpession of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol Online. 2014;32:490–494.
   PubMed Web of Science ®Google Scholar
• Kraaij T, Huizinga TWJ, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53:2122–2124.
   PubMed Web of Science ®Google Scholar
• Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45–54.
   PubMed Web of Science ®Google Scholar